Hypothesis

Longevity-associated copy-number variations (CNVs) identified in centenarians—particularly duplications of ZNF716 and LAMA5—enhance the production of tumor‑suppressive extracellular vesicles (EVs) from stromal and epithelial cells. These EVs deliver specific micro‑RNAs (e.g., miR-29 family, miR-34a) that inhibit the proliferative advantage of hematopoietic cells harboring mosaic chromosomal alterations (mCAs) such as trisomy 8 or loss of Y. Consequently, despite a higher overall CNV burden, individuals carrying these protective CNVs experience an attenuated clonal expansion of mCA-positive clones and reduced cancer incidence.

Mechanistic Rationale

1. CNV‑driven gene dosage effects – Duplications of ZNF716 (a zinc‑finger transcription factor) and LAMA5 (laminin subunit alpha5) increase expression of pathways that promote EV biogenesis and loading of tumor‑suppressive miRNAs (see et al., 2024)1.
2. EV-mediated intercellular communication – Stromal‑derived EVs are known to transfer miRNAs to hematopoietic stem/progenitor cells, modulating genes involved in self‑renewal and DNA damage response (e.g., BCL2, TP53 pathways)2.
3. Selective pressure on mCA clones – Cells with mCA‑induced oncogenic gains (e.g., KRAS amplification) rely on high proliferative signaling; miR-29/miR-34a suppress DNMT3B and BCL2, lowering survival advantage and prompting apoptosis or senescence.
4. Decoupling CNV load from cancer risk – In centenarians, the net effect is a higher total CNV count but a shift toward protective, non‑clonal EVs that neutralize the fitness benefit of deleterious mCA clones, explaining why cancer incidence does not rise proportionally with CNV burden.

Testable Predictions

• Prediction 1: Centenarian plasma EVs will show significantly higher copy‑number‑correlated expression of ZNF716 and LAMA5 mRNA, and enrichment of miR-29a/b/c and miR-34a compared with age‑matched controls (30‑65 y).
• Prediction 2: In vitro co‑culture of hematopoietic stem cells bearing an induced mCA (e.g., CRISPR‑mediated loss of chromosome Y) with EVs from centenarian‑derived fibroblasts will reduce clone frequency by ≥30 % after 14 days, whereas EVs from young donors will have no effect.
• Prediction 3: Longitudinal tracking of a cohort (≥500 individuals) will reveal that baseline plasma EV miR-29/miR-34a levels inversely predict the rate of mCA clonal expansion (measured by serial blood sequencing) independent of baseline CNV load.
• Prediction 4: Knock‑down of ZNF716 or LAMA5 in centenarian‑derived stromal cells will diminish EV miRNA loading and abolish the protective effect on mCA‑bearing hematopoietic cells in co‑culture assays.

Falsifiability

If any of the above predictions fail—e.g., centenarian EVs lack elevated tumor‑suppressive miRNAs, or EV transfer does not alter mCA clone dynamics—the hypothesis would be falsified, suggesting that longevity‑associated CNVs act through alternative mechanisms (e.g., cell‑intrinsic DNA repair) or are merely passive passengers.

Experimental Approach (brief)

• Isolate stromal fibroblasts from skin biopsies of centenarians (n=20) and younger controls (n=20).
• Perform low‑pass whole‑genome sequencing to confirm CNV status; quantify ZNF716/LAMA5 copy number.
• Ultracentrifuge plasma, characterize EV size/concentration (NTA), extract RNA, and run small‑RNA‑seq for miRNA profiling.
• Generate hematopoietic progenitor cells with inducible mCA using CRISPR‑Cas9; label with GFP.
• Co‑culture with EVs (normalized by particle number) and assess GFP+ fraction over time by flow cytometry.
• In vivo validation: inject EVs into mouse models of clonal hematopoiesis and monitor chimeric blood via ddPCR.

By linking specific longevity‑linked CNVs to EV‑mediated tumor suppression, this hypothesis bridges the observed increase in CNV burden with the paradoxically low cancer incidence in extreme aging, offering a concrete, falsifiable pathway for further study.